ReviewMolecular and cellular biochemistry2021
Cervical cancer development, chemoresistance, and therapy: a snapshot of involvement of microRNA.
Review in Molecular and cellular biochemistry, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 1 synthesis or guideline pooled it, 36 citations in OpenAlex.
- Emerging Role of MicroRNAs in the Therapeutic Response in Cervical Cancer: A Systematic Review.Frontiers in oncology · 2022Pooled it
- Synergistic anticancer effects of thymoquinone and curcumin via ROS-mediated mitochondrial apoptosis in HeLa cells.Molecular biology reports · 2026Article
- The Chick Embryo Chorioallantoic Membrane Assay as a Short-Term Exploratory Model for Cervical Cancer Research.Life (Basel, Switzerland) · 2026Article
- Advances in exosomal non-coding RNAs in cervical cancer (Review).Molecular and clinical oncology · 2025Review
- Article
- Exosomal miRNA-based theranostics in cervical cancer: bridging diagnostics and therapy.Medical oncology (Northwood, London, England) · 2025Review
- Long non-coding RNA H19 promotes cervical cancer development via targeting the microRNA-140/ALDH1A1 axis.European journal of medical research · 2025Article
- Membrane transporter genes predict chemoradiotherapy response in patients with cervical cancer.Einstein (Sao Paulo, Brazil) · 2025Article
- Comparative Analysis of Digital Transcriptomics Between Pre- and Post-Treatment Samples of Patients with Locally Advanced Cervical Cancer: A Preliminary Study.Current issues in molecular biology · 2024Article
- Alterations in miRNA Expression and Their Role in the Pathogenesis of Cervical Cancer.Asian Pacific journal of cancer prevention : APJCP · 2024Article
- Knockdown of miR-24 Suppressed the Tumor Growth of Cervical Carcinoma Through Regulating PTEN/PI3K/AKT Signaling Pathway.Biochemical genetics · 2024Article
- Therapeutic Strategies in Advanced Cervical Cancer Detection, Prevention and Treatment.OncoTargets and therapy · 2024Review
- Understanding the role of miRNAs in cervical cancer pathogenesis and therapeutic responses.Frontiers in cell and developmental biology · 2024Review
- Overview of miR-106a Regulatory Roles: from Cancer to Aging.Bioengineering (Basel, Switzerland) · 2023Review
- Human Papilloma Virus: An Unraveled Enigma of Universal Burden of Malignancies.Pathogens (Basel, Switzerland) · 2023Review
- Review
- miR-96-5p regulates cervical cancer cell resistance to cisplatin by inhibiting lncRNA TRIM52-AS1 and promoting IGF2BP2.The Kaohsiung journal of medical sciences · 2022Article
- MiR-95-3p acts as a prognostic marker and promotes cervical cancer progression by targeting VCAM1.Annals of translational medicine · 2022Article
- Targeting Genetic Modifiers of HBG Gene Expression in Sickle Cell Disease: The miRNA Option.Molecular diagnosis & therapy · 2022Review
- Emodin Sensitizes Cervical Cancer Cells to Vinblastine by Inducing Apoptosis and Mitotic Death.International journal of molecular sciences · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cervical cancer (CC) is one of the leading causes of death in women due to cancer and a major concern in the developing world. Persistent human papilloma virus (HPV) infection is the major causative agent for CC. Besides HPV infection, genetic and epigenetic factors including microRNA (miRNA) also contribute to the malignant transformation. Earlier studies have revealed that miRNAs participate in cell proliferation, invasion and metastasis, angiogenesis, and chemoresistance processes by binding and inversely regulating the target oncogenes or tumor suppressor genes. Based on functions and mechanistic insights, miRNAs have been identified as cellular modulators that have an enormous role in diagnosis, prognosis, and cancer therapy. Signatures of miRNA could be used as diagnostic markers which are necessary for early diagnosis and management of CC. The therapeutic potential of miRNAs has been shown in CC; however, more comprehensive clinical trials are required for the clinical translation of miRNA-based diagnostics and therapeutics. Understanding the molecular mechanism of miRNAs and their target genes has been useful to develop miRNA-based therapeutic strategies for CC and overcome chemoresistance. In this review, we summarize the role of miRNAs in the development, progression, and metastasis of CC as well as chemoresistance. Further, we discuss the diagnostic and therapeutic potential of miRNAs to overcome chemoresistance and treatment of CC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.